RT @JIMD_Editors: Staying with VLCADD, an #openaccess paper from Bleeker et al looked at 10 years of screening in the Netherlands - they fo…
RT @JIMD_Editors: Staying with VLCADD, an #openaccess paper from Bleeker et al looked at 10 years of screening in the Netherlands - they fo…
Staying with VLCADD, an #openaccess paper from Bleeker et al looked at 10 years of screening in the Netherlands - they found that screening prevented hypoglycemiia in those with residual enzyme activity, but not with very low residual enzyme activity. http
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
RT @JIMD_Editors: Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & card…
Bleeker et al discuss impact of NBS on VLCADD. Low BSL in patients with some enzyme activity improved but low BSL & cardiac complications in very low residual activity persist. Impact on prevalence/prevention of myopathy‐related complications is uncle